Lessons From The Largest Patent Damages Award In History
By Barry Herman, Womble Carlyle Sandridge & Rice LLP (January 20, 2017, 10:42 AM EST) -- By now, most everyone in the patent community has heard about the $2.54 billion jury verdict in a battle over Hepatitis C medication that resulted from a jury trial in December 2016. In Delaware federal district court, Idenix Pharmaceuticals Inc. (now owned by Merck & Co. Inc.) and Gilead Sciences Inc. faced off in a patent trial roughly three years after Gilead introduced its blockbuster Hepatitis C drugs, Sovaldi and Harvoni.
While a case such as this will certainly be litigated further in post-trial motions and eventually on appeal to the Federal Circuit, I was very curious to understand how the...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!